Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-labeled RBC PET-CT for Cardiac Monitoring in Breast Cancer
NCT03295695Phase 1Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Moffitt Cancer Center. Primary endpoint: Cardiac Ejection Fraction up to 12 months. Planned start Dec 2020; status: withdrawn.
Beyond the preview
Go deeper on NCT03295695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295695.